Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

Chang, Hye-Jin;Lee, Jung-Ryeol;Jee, Byung-Chul;Suh, Chang-Suk;Kim, Seok-Hyun

  • Published : 2009.04.20
⟨ Previous Next ⟩

Abstract

This study was performed to analyze retrospectively outcomes of stimulated in vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH) antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF cycles were included in 65 women who are undergoing ovarian stimulation with recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when leading follicle reached 14 mm in diameter until the day of hCG administration (Group A, 66 cycles) or until the day before hCG administration (Group B, 26 cycles). The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and the number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in Group B compared to Group A ($2.7{\pm}0.8$ vs. $3.2{\pm}0.9$ ampoules). There was no premature luteinization in the subjects. The proportion of mature oocytes (71.4% vs. 61.7%) and fertilization rate of mature ($86.3{\pm}19.7%$ vs. $71.8{\pm}31.7%$) was significantly higher in Group B. There were no significant differences in embryo quality and clinical pregnancy rates. Our results suggest that cessation of the GnRH antagonist on the day of hCG administration during a flexible multipledose protocol could reduce the total dose of GnRH antagonist without compromising IVF results.

Keywords

References

  1. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmuller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994; 9: 788-91.
  2. Olivennes F. The use of gonadotropin-releasing hormone antagonist in ovarian stimulation. Clin Obstet Gynecol 2006; 49: 12-22. https://doi.org/10.1097/01.grf.0000197520.53682.32
  3. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17: 874-85. https://doi.org/10.1093/humrep/17.4.874
  4. The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophinreleasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 1998;13: 3023-31. https://doi.org/10.1093/humrep/13.11.3023
  5. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin. Gynecol Endocrinol 2005; 20: 161-9. https://doi.org/10.1080/09513590400027232
  6. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LHRH agonist (triptorelin). Fertil Steril 2000; 73: 314-20. https://doi.org/10.1016/S0015-0282(99)00524-5
  7. Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. Reprod Biomed Online 2003; 7: 185-9. https://doi.org/10.1016/S1472-6483(10)61749-X
  8. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; 3: CD001750.
  9. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used- A systematic review and meta-analysis. Hum Reprod Update 2006; 12: 651-71. https://doi.org/10.1093/humupd/dml038
  10. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF- Hum Reprod 2007; 22: 2805-13. https://doi.org/10.1093/humrep/dem270
  11. Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice- Data from the German national IVF registry. Hum Reprod 2005;20: 2373-5. https://doi.org/10.1093/humrep/dei086
  12. Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod 2006; 21: 352-7. https://doi.org/10.1093/humrep/dei348
  13. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 2003; 88: 5632-7. https://doi.org/10.1210/jc.2003-030805
  14. Frankfurter D, Dayal M, Dubey A, Peak D, Gindoff P. Novel follicular- phase gonadotropin-releasing hormone antagonist stimulation protocol for in vitro fertilization in the poor responder. Fertil Steril 2007; 88: 1442-5. https://doi.org/10.1016/j.fertnstert.2007.01.022
  15. Griesinger G, Dawson A, Schultze-Mosgau A, Finas D, Diedrich K, Felberbaum R. Assessment of luteinizing hormone level in the gonadotropin- releasing hormone antagonist protocol. Fertil Steril 2006;85: 791-3. https://doi.org/10.1016/j.fertnstert.2005.08.048
  16. Allegra A, Marino A, Coffaro F, Scaglione P, Sammartano F, Rizza G, Volpes A. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod 2007; 22: 101-8. https://doi.org/10.1093/humrep/dem1065
  17. Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin- releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow- Fertil Steril 2005;83: 1607-11. https://doi.org/10.1016/j.fertnstert.2005.02.011
  18. Brown JB. Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol 1978; 18:46-54.
  19. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994; 9: 188-91.
  20. Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000; 15: 1211-6. https://doi.org/10.1093/humrep/15.6.1211
  21. Ortmann O, Diedrich K. Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues. Hum Reprod 1999; 14 (Suppl 1): 194-206. https://doi.org/10.1093/humrep/14.suppl_1.194
  22. Grundker C, Gunthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002; 87: 1427-30. https://doi.org/10.1210/jc.87.3.1427
  23. Peng C, Fan NC, Ligier M, Vaananen J, Leung PC. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 1994; 135: 1740-6. https://doi.org/10.1210/en.135.5.1740
  24. Ikemoto T, Park MK. Comparative analysis of the pituitary and ovarian GnRH systems in the leopard gecko: signaling crosstalk between multiple receptor subtypes in ovarian follicles. J Mol Endocrinol 2007; 38: 289-304. https://doi.org/10.1677/JME-06-0010
  25. Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, Itskovitz-Eldor J. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod 1999; 14: 2242-4. https://doi.org/10.1093/humrep/14.9.2242
  26. Lee JR, Choi YS, Jee BC, Ku SY, Suh CS, Kim KC, Lee WD, Kim SH. Cryopreserved blastocyst transfer: impact of gonadotropinreleasing hormone agonist versus antagonist in the previous oocyte retrieval cycles. Fertil Steril 2007; 88: 1344-9. https://doi.org/10.1016/j.fertnstert.2007.01.013
  27. Simon C, Oberye J, Bellver J, Vidal C, Bosch E, Horcajadas JA, Murphy C, Adams S, Riesewijk A, Mannaerts B, Pellicer A. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod 2005; 20:3318-27. https://doi.org/10.1093/humrep/dei243
  28. Saadat P, Boostanfar R, Slater CC, Tourgeman DE, Stanczyk FZ, Paulson RJ. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. Fertil Steril 2004; 82: 167-71. https://doi.org/10.1016/j.fertnstert.2003.11.050
  29. Chen HJ, Lin YH, Hsieh BC, Seow KM, Hwang JL, Tzeng CR. Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation- J Assist Reprod Genet 2006; 23: 289-92. https://doi.org/10.1007/s10815-006-9054-0
  30. Messinis IE, Loutradis D, Domali E, Kotsovassilis CP, Papastergiopoulou L, Kallitsaris A, Drakakis P, Dafopoulos K, Milingos S. Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment. Hum Reprod 2005; 20: 3192-7. https://doi.org/10.1093/humrep/dei210
  31. Huirne JA, van Loenen AC, Schats R, McDonnell J, Hompes PG, Schoemaker J, Homburg R, Lambalk CB. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod 2005; 20: 359-67. https://doi.org/10.1093/humrep/deh601
  32. Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization- A systematic review and metaanalysis. Hum Reprod Update 2007; 13: 343-55. https://doi.org/10.1093/humupd/dmm007

Cited by

  1. Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study vol.40, pp.2, 2009, https://doi.org/10.5653/cerm.2013.40.2.83
  2. Relationship between follicular fluid adipocytokines and the quality of the oocyte and corresponding embryo development from a single dominant follicle in in vitro fertilization/intracytoplasmic sperm vol.41, pp.1, 2009, https://doi.org/10.5653/cerm.2014.41.1.21
  3. Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis vol.30, pp.6, 2014, https://doi.org/10.3109/09513590.2014.895984
  4. GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve vol.12, pp.None, 2021, https://doi.org/10.3389/fendo.2021.758896